80
Antimicrobial therapy in horses: a pharmacologist perspective Pierre-Louis Toutain National Veterinary School; Toulouse ,France 30th October 2014; Department of Veterinary Disease Biology University of Copenhagen

Antimicrobial therapy in horses: a pharmacologist perspective

Embed Size (px)

DESCRIPTION

Antimicrobial therapy in horses: a pharmacologist perspective. Pierre-Louis Toutain National Veterinary School; Toulouse ,France 30th October 2014; Department of Veterinary Disease Biology University of Copenhagen. Steps for a rationale selection of an antimicrobial (AM) drug. - PowerPoint PPT Presentation

Citation preview

Page 1: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Antimicrobial therapy in horses: a pharmacologist perspective

Pierre-Louis ToutainNational Veterinary School; Toulouse ,France

30th October 2014; Department of Veterinary Disease Biology

University of Copenhagen

Page 2: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Steps for a rationale selection of an antimicrobial (AM) drug

1. Identity of the affecting MO2. In vitro AM susceptibility of the bug3. Nature and site of infection4. The pharmacokinetic (PK) characteristics of the

selected AM5. The pharmacodynamics (PD) properties of the

selected AM6. PK and PD integration (PK/PD indices)7. Safety issues8. Cost of the therapy

Page 3: Antimicrobial  therapy in  horses:  a pharmacologist perspective

1-Why plasma concentrations are relevant for AMD and why to

compare free plasma concentration to MICs?

Page 4: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Nature and site of infectionWhere are located the pathogens

Extra Cellular FluidMost bacteria of clinical interest- respiratory infection- wound infection- digestive tract inf.

Cell(in phagocytic cell most often)• Legionnella spp• mycoplasma (some)• chlamydiae• Brucella• Cryptosporidiosis• Listeria monocytogene• Salmonella• Mycobacteria• Rhodococcus equi

BoundBound

Free±MIC

Free MO

Page 5: Antimicrobial  therapy in  horses:  a pharmacologist perspective

2-The right dosage regimen to control the efficacious

plasma concentration

Page 6: Antimicrobial  therapy in  horses:  a pharmacologist perspective

What are the elements of a dosage regimen

• The dose–A PK/PD variable

• The dosing interval• The treatment duration

–When to start–When to finish

Page 7: Antimicrobial  therapy in  horses:  a pharmacologist perspective

8

A fundamental relationship

A dose can be determined rationally using a PK/PD approach

!

PKPKPD

X MICPD

X MIC

PK(0 to 1)

PK(0 to 1)

PK(0 to 1)

PK(0 to 1)

Page 8: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Question: what is the daily dose for enrofloxacin for different possible MIC90

• What we know:– Plasma clearance: 2.5L/Kg/24h– Bioavailability by intragastric route of 80%– Extent of binding of ~ 20%– MIC90

– The PK/PD index for optimization: AUC/MIC=125• Or equivalently : the average plasma concentration over the dosing interval

should be 5 folds the MIC

MO µg/mLE. Coli ; S. aureus 0.25

Pseudomonas aeruginosa 0.50Strept. zooepidemicus 1.00

Rhodococcus equi 2.00

Page 9: Antimicrobial  therapy in  horses:  a pharmacologist perspective

It has been developed surrogates indices (predictors) of antibiotic efficacy taking into account MIC (PD) and exposure antibiotic

metrics (PK)

Practically, 3 indices cover all situations:•AUC/MIC •Time>MIC• Cmax/MIC

Practically, 3 indices cover all situations:•AUC/MIC •Time>MIC• Cmax/MIC

Page 10: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Recommandations thérapeutiques en fonction de la bactéricide

Pattern de la bactéricidie

Antibiotiques Objectifs

therapeutiques

Paramètre

PKPD

Type I

Concentration dépendant & effets

prolongés

Aminoglycosides

Quinolones

Optimiser les concentrations

Cmax/MIC

24h-AUC/MIC

Type II

Temps dépendant & pas de

rémanence

Pénicillines

Céphalosporines

Optimiser la durée

d’exposition

T>MIC

Type III

Temps dépendant & effets rémanents

dose-dépendant

Macrolides

Tétracyclines

Optimiser les quantités (doses)

24h-AUC/MIC

Page 11: Antimicrobial  therapy in  horses:  a pharmacologist perspective

The dose for enrofloxacin

MO MIC: µg/mLE. Coli ; S. aureus 0.25

Pseudomonas aeruginosa 0.50Strept. zooepidemicus 1.00

Rhodococcus equi 2.00

Page 12: Antimicrobial  therapy in  horses:  a pharmacologist perspective

The dose for enrofloxacinAUC/MIC=125

MO MIC (µg/mL) Dose (mg/kg)

E. Coli ; S. aureus 0.25 4.9

Pseudomonas aeruginosa 0.50 9.77

Strept. zooepidemicus 1.00 19.5

Rhodococcus equi 2.00 39.1

Page 13: Antimicrobial  therapy in  horses:  a pharmacologist perspective

3-Variability of plasma clearance in horses

15

Drugs, ageDrugs, age

Page 14: Antimicrobial  therapy in  horses:  a pharmacologist perspective

16

AMD: plasma clearancesLow or high?Low or high?

Drug ClB

(mL/kg/min)Sulphadoxine 0.32Gentamicin 1.2

Sulphamethoxazole 1.2Amikacin 1.23

Oxytetracycline 1.25Rifampin 1.34

Sulphadiazine 1.45Cefoxitin 1.72

Metronidazole 1.97Enrofloxacin 2.33

Ampicillin 2.89Ticarcillin 3.1

Amoxicillin 4.55

Drug ClB

(mL/kg/min)Trimethoprim 5.03

Ceftriaxone 5.22Cafazolin 5.27Cefadroxil 6.95Penicillin 8.5

Chloramphenicol 8.8Ciprofloxacin 9.7; 18

Clarithromycin 21.1Erythromycin 26.6

Page 15: Antimicrobial  therapy in  horses:  a pharmacologist perspective

17

AMD: plasma clearancesEffect of ageEffect of age Effect of breed, fever, sex, ….Effect of breed, fever, sex, ….

A foal is not only a small horse

Page 16: Antimicrobial  therapy in  horses:  a pharmacologist perspective

18

AMD: protein binding

Low or high?Low or high?• MIC are free concentrations• Only the free concentration is active• No example of drug/drug interaction

leading to increase the free drug concentration by displacement (eg with NSAID)

• MIC are free concentrations• Only the free concentration is active• No example of drug/drug interaction

leading to increase the free drug concentration by displacement (eg with NSAID)

Page 17: Antimicrobial  therapy in  horses:  a pharmacologist perspective

19

AMD: bioavailability

Low or high?Low or high?

Large influence of the route of administration and of the formulations

Large influence of the route of administration and of the formulations

Page 18: Antimicrobial  therapy in  horses:  a pharmacologist perspective

• Bioavailability quantifies the proportion

of a drug that is absorbed and

available to produce its systemic effect

– Extent (overall exposure)

– Rate (T>MIC)

Bioavailability

Page 19: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Bioavailability

Definition• Absolute

– amount of administered drug which enters the systemic (arterial) circulation and the rate at which the drug appears in the blood stream

• Relative– to compare formulations (bioequivalence)– to compare routes of administration

Page 20: Antimicrobial  therapy in  horses:  a pharmacologist perspective

IV route of administrationby definition F=100%

22

Not always the case for AMD administered as prodrug such as esters as erythromycin estolate

Not always the case for AMD administered as prodrug such as esters as erythromycin estolate

Page 21: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Oral route of administration

24

Page 22: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Oral route: several possible modalities

25

Intragastric

Perlingual

Mash

Fed vs unfed (food withheld for 12h )Fed vs unfed (food withheld for 12h )

Page 23: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Oral enrofloxacin : no food effect

Steinman et al JPT 2006

5 mg/kg

Fasted Hay concentrateAUC

(µg.h/ml) 18.5 12.5 13.9

T1/2 (h) 8.1 7.6 7.9

Cmax (µg/ml) 1.7 1 1.3

Page 24: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Rifampin administration before and after feeding

The Royal Veterinary College Peter Lees July 2003

Bioavailability: 68% (fasted) vs 26% (fed)28

Page 25: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Influence of food on the F% of erythromycin (base)

29

Food withheld=26% (6-44%)

Fed =7.7% (1-18%)Fed =7.7% (1-18%)

Lakritz et al AJVR, Vol 61, No. 9, September 2000

Foals should be given ERY before they are fed hay. Administrationof ERY to foals from which food was withheld overnight apparently provides plasma concentrations of erythromycin A that exceed the minimum inhibitory concentration of Rhodococcus equi for approximately 5 hours. The dosage of 25 mg/kg every 8 hours, PO, appears appropriate.

Foals should be given ERY before they are fed hay. Administrationof ERY to foals from which food was withheld overnight apparently provides plasma concentrations of erythromycin A that exceed the minimum inhibitory concentration of Rhodococcus equi for approximately 5 hours. The dosage of 25 mg/kg every 8 hours, PO, appears appropriate.

Page 26: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Why a possible low oral bioavailability

• Poor stability in the stomach– pH effect

• Poor absorption– Physiological origin– Binding to cellulosis

• Hepatic first-pass effect– Can be predicted from the blood clearance

• Drug interaction

31

Page 27: Antimicrobial  therapy in  horses:  a pharmacologist perspective

In vitro binding (%) of TMP and sulphachlorpyridazine to hay, grass silage and concentrate

Medium(3h at 37C)

% Binding Trimethoprim

% Binding Sulphachlorpyridazine

Concentrations 4 mg/ml 100 mg/ml 4 mg/ml 100 mg/ml

Hay 82 63 90 67

Grass silage 73 47 71 33

Concentrate 64 36 86 64

Van Duijkeren, 1996

Page 28: Antimicrobial  therapy in  horses:  a pharmacologist perspective

The pH effect(stomach)

33

Page 29: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Poor stability of the AM in the stomach: the case of erythromycin

• Inactivated by gastric acid thus:– Enteric-coated formulations – Esters (prodrugs) with improved acid stability but

requiring hydrolysis by esterases• Estolate• Stearate• ethyl succinate

34

However a horse and a man can be different and extrapolation misleading

However a horse and a man can be different and extrapolation misleading

Page 30: Antimicrobial  therapy in  horses:  a pharmacologist perspective

35

Gastric pH

Time0

1

2

3

4

5

6

7

pH

Time0

1

2

3

4

5

6

7

8

pH

FastedLow pH (average of 1.6)Continuous secretion

FastedLow pH (average of 1.6)Continuous secretion

Hay ad libitumBuffering capacity of hay and saliva (at each peak)Hay ad libitumBuffering capacity of hay and saliva (at each peak)

Page 31: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Erythromycin: bioinequivalence of the different forms

• Three possible forms for an oral administration– Erythromycin base– Erythromycin salt (lactobionate, phosphate…)– Erythromycin esters absorbed by the GIT (estolate,

etylsuccinate)– Erythromycin ester hydrolysed in the GIT (stearate)

36

Phosphate (salt)

Estolate(ester)

Stearate(ester)

Ethylsuccinateester

AUC (µg*h/mL) 295 176 302 308

Cmax (µg/mL) 2.3 0.4 2 0.3

T1/2, (min) 149 145 110 221Poor

absorption Slow hydrolysis

Page 32: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Effect of age on bioavailability

37

Page 33: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Age effect: Bioavailability of IG Cefadroxil in foal

Duffee JVPT 1997 20 427

Age (months)

0.5 1 2 3 5

F% 99.6 67.6 35.1 19.5 14.4

Tmax (h) 2.1 1.6 1.6 .96 .90

38

Page 34: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Effect of age on bioavailability of oral penicillins in the horse

Drug F (%) In foal F (%) in adult

Penicillin V(phenoxymethyl

penicillin)16.00 2.00

Amoxycillin 36-42 5 - 10

Page 35: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Why a possible low oral bioavailability

• Poor stability in the stomach– pH effect

• Poor absorption– Physiological origin– Binding to cellulosis

• Hepatic first-pass effect– Can be predicted from the blood clearance

• Drug interaction

40

Page 36: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Poor absorption due to drug-drug interaction

Page 37: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Association of AMDClarithromycin ± Rifampin

• After RIF comedication, relative bioavailability of CLR decreased by more than 90%.• the drastic lowering of the average CLR plasma concentrations by more than 90% have

resulted from induction of hepatic and intestinal CYP3A4 and intestinal ABCB1 and probably

• ABCC2. efflux transport seems to be the major reason for lower bioavailability• there are many doubts from a pharmacokinetic point of view that combination therapy of CLR with

RIF might really be superior to other eradication protocols as suggested by the results of a retrospective clinical study in foals (Gigue`re et al., 2004). The absence of major drug interactions as shown in our recent pharmacokinetic study with tulathromycin and RIF should be confirmed before a combination treatment is launched in clinical practice (Venner et al., 2010).

42

Page 38: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Poor bioavailability due to a hepatic first-pass effect

43

Page 39: Antimicrobial  therapy in  horses:  a pharmacologist perspective

The 3 segments of the digestive tract in terms of first-pass effect

44

Buccal cavityNo

first-passeffect

Small intestine/large bowelFull First pass-effect

Rectal Limited

first-pass effect

Rectal Limited

first-pass effect

Page 40: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Hepatic first pass effect

45• Fmax = 1 – Eh=1 - [Clh / Qh]=1-[17/24]=0.30• Fmax = 1 – Eh=1 - [Clh / Qh]=1-[17/24]=0.30

LiverFmax = 1 - Eh

Eythromycin Dose

Eh~70%Fraction eliminated by first pass effect

30%

Page 41: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Plasma erythromycin after an IG administration of a salt (phosphate) or an ester (estolate) of

erythromycin (food withheld)

47

Plasma clearance of erythromycin is very large (17.5ml/kg/min) suggesting a likely large hepatic first-pass effect in horse

Plasma clearance of erythromycin is very large (17.5ml/kg/min) suggesting a likely large hepatic first-pass effect in horse

F% from Phosphate:16±3.5%F% from estolate: 14.7±11%Both are very low: why?

F% from Phosphate:16±3.5%F% from estolate: 14.7±11%Both are very low: why?

Page 42: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Intramuscular administration

Page 43: Antimicrobial  therapy in  horses:  a pharmacologist perspective

IV administration of sodium benzylpenicillin

Page 44: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Penicillin G potassium vs. Penicillin G procaine

Flip-flop kinetics

Procaine benzylpenicillin ( procaine penicillin) is an ester of benzylpenicillin and the local anaesthetic agent procaine. Following deep intramuscular injection, it is slowly absorbed into the circulation and hydrolysed to benzylpenicillin This combination is aimed at reducing the pain and discomfort associated with a large intramuscular injection of penicillin.

Procaine benzylpenicillin ( procaine penicillin) is an ester of benzylpenicillin and the local anaesthetic agent procaine. Following deep intramuscular injection, it is slowly absorbed into the circulation and hydrolysed to benzylpenicillin This combination is aimed at reducing the pain and discomfort associated with a large intramuscular injection of penicillin.

Page 45: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Influence of the injection site on bioavailability of Penicillin (administration of procaine benzylpenicilin)

Influence of the injection site on bioavailability of Penicillin (administration of procaine benzylpenicilin)

Semi-membrane / semi-tendineux

0 2 4 6 8 10 12 24h

(Time)0

1

2

3

4

Con

cent

ratio

ns (

UL/

mL)

M. serratusM. bicepsM. pectoralisM. gluteusM. Subcutaneous

Firth et al. 1986, Am. J. Vet. Res.

Page 46: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Terminal half-life and bioavailability of procaine benzylpenicillin in the horse

Injection site Terminal half-life (h) Bioavailability (%)

Subcutaneous 21.8 78.4Intramuscular :

M.gluteus 12.8 78.4M.pectoralis 14.9 94.2

M.biceps 14.9 97.6M.serratus 8 113.2Intravenous 3.72 100

The terminal half-life is much more longer after an extravascular administration:The so-called flip-flop phenomenon

Page 47: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Intra- vs intermuscular administrationIntra- vs intermuscular administration

• The best site for IM administration is the 5th

cervical vertebra, ventral to the funicular part of the ligamentum nuchae but dorsal to the brachiocephalic muscle

Boyd et al,1987, Vet. Rec.

True IM

Page 48: Antimicrobial  therapy in  horses:  a pharmacologist perspective

3Preanalytical method 06 - 54

Intra- vs intermuscular administrationIntra- vs intermuscular administration• Injection in the 4th space but the ventral injection

has traversed to the 6th vertebral space

Boyd et al,1987, Vet. Rec.

Page 49: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Procaine penicillin adverse effects

• PP is associated with incidence of severe adverse reactions with distress…...but much less frequently with water-soluble salts of Penicillin.– Anaphylactic reaction: rare in horses

• Penicillin have affinity to proteins and may form hapten• Hypersensitivity is the most common cause of negative

reaction to penicillin

– Procaine toxicity: frequent in horses• Due to action of the free procaine on the CNS

56

Page 50: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Procaine penicillin adverse effects• Procaine is hydrolysed by plasma esterase to

non toxic metabolite (Para-aminobenzoic acid and Diaminoethanol)

• Toxicity is observed if the rate of Procaine absorption exceeds the hydrolyzing capacity– Inadvertent IV route after an IM administration– Poor esterase activity (next slide)– Some formulations have high free procaine

concentration (vehicule) and this is increase by high room temperature (stability issue)

57

Page 51: Antimicrobial  therapy in  horses:  a pharmacologist perspective

PP adverse effects: esterase activity

58

Poor esterase activity in horses havingADRPoor esterase activity in horses havingADR

Page 52: Antimicrobial  therapy in  horses:  a pharmacologist perspective

The question of medication/doping control for penicillin procaine

• Normally, no routine screening for doping control for the AMD

• But procaine is controlled (as a local anesthetic)– What about penicillin procaine? – Can be very long in urine (several months)

Page 53: Antimicrobial  therapy in  horses:  a pharmacologist perspective

The EHSLC web site

Click on the image

Page 54: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Local tolerance of AMD• Poorly tolerated

– aminoglycosides– TMP/sulfate– macrolides– tétracyclines

• Well tolerated– Penicillines (peni-procaine better than

penicillin G)

Page 55: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Inhalation

63

Page 56: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Cortic 00A.64

Many devices: are they equivalent?

Page 57: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Cortic 00A.65

Page 58: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Cefquinome inhalation:high local concentration

• Very high local drug concentrations of cefquinome was achieved in horses using a jet nebulizer, but cefquinome was not detectable after 4 h in the majority of horses– This is likely true for any drug that was not

specifically developed for inhalation (e.g. dexamethasone) because pulmonary absorption is very fast due to a very high blood flow.

66

Page 59: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Inhalation treatment: an user safety issue?

• During exhalation, some degree of air pollution of the drug was evident and user safety was accounted for by ventilating the room sufficiently during administration

67

Page 60: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Drug elimination and PK selectivity

Page 61: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Selectivity of antimicrobial drugs in veterinary medicine

Page 62: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Almost all oral and parenterally administered antimicrobials have been linked with antimicrobial associated diarrhoea (AAD) in both man and horses, although some antimicrobials clearly pose a higher risk:•Macrolides ( erythromycine, tylosine, …)•Tetracyclines (doxycyclin, OTC…)•Bêtalactams (Penicillin G, ampicillin, ceftiofur..)

Almost all oral and parenterally administered antimicrobials have been linked with antimicrobial associated diarrhoea (AAD) in both man and horses, although some antimicrobials clearly pose a higher risk:•Macrolides ( erythromycine, tylosine, …)•Tetracyclines (doxycyclin, OTC…)•Bêtalactams (Penicillin G, ampicillin, ceftiofur..)

Page 63: Antimicrobial  therapy in  horses:  a pharmacologist perspective

AMD effect on the enteric anaerobes

• The potential of an antimicrobial to induce AAD is largely dependent on its effect on the enteric anaerobes, which in turn reflects its spectrum of antibacterial activity, and the concentration of active drug within the intestine– lincosamides, macrolides and b-lactams

have efficacy against anaerobes

Page 64: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Factors determining AMD concentration in the gut

• the route of administration– IV vs. oral for oxytetracyclines

• the % of drug absorbed from the intestine – Low bioavailability of many AMD– Food effect

• The % excreted in bile or mucus– Macrolides (bile), doxycycline (enterocytes)– Large differences between quinolones (enro vs. cipro)

• The extent to which the drug is inactivated by the intestinal contents

Page 65: Antimicrobial  therapy in  horses:  a pharmacologist perspective

• Anecdotally, there appear to be geographical differences in the susceptibility of the local equine population to develop AAD after administration of a particular antimicrobial

• This mayreflect regional differences in the composition of the enteric flora

Page 66: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Both hospitalisation and the use of AMD were associated with prevalence of AMR among E coli isolated from the feces of horse (Dunowska at al JAVMA 2006 228 1909Both hospitalisation and the use of AMD were associated with prevalence of AMR among E coli isolated from the feces of horse (Dunowska at al JAVMA 2006 228 1909

Page 67: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Pharmacodynamic of antibiotic in horses

Page 68: Antimicrobial  therapy in  horses:  a pharmacologist perspective

76

A fundamental relationship

A dose can be determined rationally using a PK/PD approach

!

PKPD

X MICPD

X MIC

PK(0 to 1)

PK(0 to 1)

Page 69: Antimicrobial  therapy in  horses:  a pharmacologist perspective

CLSI breakpoints for the horse 2014(µg/mL)

Conditions Antibiotics Pathogens S I R Comments

Gentamicin

Enterobacteriaceae ≤2 4 ≥8 Breakpoints derived from microbiological, pharmacokinetic (using accepted clinical doses), and pharmacodynamic data. For horses, the dose of gentamicin modeled was 6.6 mg/kg

every 24 hours, IM.Pseudomonas aeruginosa ≤2 4 ≥8

Actinobacillus spp. ≤2 4 ≥8

Horses Respiratory Disease Ampicillin

Streptococcus equi subsp. ≤0.25

For horses, the dose of ampicillin sodium modeled was 22 mg/kg IM every 12 hourszooepidemicus and

subsp. equi ≤0.25

Horses (Respiratory, Soft Tissue) Penicillin

Staphylococcus spp. ≤0.5 1 ≥2 Breakpoints derived from microbiological, pharmacokinetic data (using accepted clinical, but extra-label doses), and pharmacodynamic data. The dose of procaine penicillin G modeled was 22 000 U/kg, IM, every 24 hours.Streptococcus spp. ≤0.5 1 ≥2

Horses (respiratory, genital tract) Cefazolin

Streptococci – β-hemolytic group Escherichia coli

≤2 4 ≥8

Cefazolin breakpoints were determined from an examination of MIC distribution of isolates and PK-PD analysis of cefazolin. The dosage regimen used for PK-PD analysis of cefazolin was 25 mg/kg administered every six hours intravenously in horses and dogs.

Horses Respiratory Disease Ceftiofur Streptococcus equi

subsp. zooepidemicus ≤0.25

Page 70: Antimicrobial  therapy in  horses:  a pharmacologist perspective

In vitro veritas

Page 71: Antimicrobial  therapy in  horses:  a pharmacologist perspective

MICs estimated with different inoculmum densities, relative to that MIC at 2x105

Ciprofloxacin

Gentamicin

Linezolid

Daptomycin

Oxacillin

Vancomycin

Page 72: Antimicrobial  therapy in  horses:  a pharmacologist perspective

In vitro veritas?

Page 73: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Evaluation of tulathromycin in the treatment of pulmonary abscesses (Rhodococcus equi) in foals

Venner et al Vet J 2006

Azithromycin+RifampinAzithromycin+RifampinTulathromycinTulathromycin

The combination of a macrolide and rifampin is synergistic both in vitro and in vivo, and the use of the 2 classes of drugs in combination reduces the likelihood of R. equi esistance to either drugThe combination of a macrolide and rifampin is synergistic both in vitro and in vivo, and the use of the 2 classes of drugs in combination reduces the likelihood of R. equi esistance to either drug

Page 74: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Tulathromycin: MIC (ng/mL) in MHB vs. calf serum25%,50%,75% and 100%

25% 50% 75% 100 %

Page 75: Antimicrobial  therapy in  horses:  a pharmacologist perspective

The serum effect

For azithromycin (closely related to tulathromycin) the presence of 40% serum during the MIC test decreasedMICs by 26-fold for serum-resistant Escherichia coli and 15-fold for Staphylococcus aureus.

For azithromycin (closely related to tulathromycin) the presence of 40% serum during the MIC test decreasedMICs by 26-fold for serum-resistant Escherichia coli and 15-fold for Staphylococcus aureus.

Page 76: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Rhodococcus equi:

Page 77: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Clarithromycin is the macrolide of choice for foals

• Clarithromycin is the macrolide of choice for foals with severe disease, given the most favorable minimum inhibitory concentration against R equi isolates obtained from pneumonic foals (90% of isolates are inhibited at 0.12, 0.25, and 1.0 mcg/mL for clarithromycin, erythromycin, and azithromycin, respectively).

• In foals with R equi pneumonia, the combination of clarithromycin (7.5 mg/kg, PO, bid) and rifampin is superior to erythromycin-rifampin and azithromycin-rifampin.

• Foals treated with clarithromycin-rifampin have improved survival rates and fewer febrile days than foals treated with erythromycin-rifampin and azithromycin-rifampin. Reported adverse effects of clarithromycin-rifampin include diarrhea in treated foals. The duration of antimicrobial therapy typically is 3–8 wk.

Page 78: Antimicrobial  therapy in  horses:  a pharmacologist perspective

In vitro veritasthe case of combination

• The combination of a macrolide (erythromycin, azithromycin, or clarithromycin) with rifampin is the recommended treatment for infection caused by R. equi, based on in vitro activity data, pharmacokinetic studies, and retrospective studies.

• The level of evidence for this recommendation is moderate, with no randomized controlled studies available to substantiate it.

Page 79: Antimicrobial  therapy in  horses:  a pharmacologist perspective

Association Clarithromycin + Rifampina major PK interaction

• After RIF comedication, relative bioavailability of CLR decreased by more than 90%.• the drastic lowering of the average CLR plasma concentrations by more than 90% have

resulted from induction of hepatic and intestinal CYP3A4 and intestinal ABCB1 and probably

• ABCC2. efflux transport seems to be the major reason for lower bioavailability• there are many doubts from a pharmacokinetic point of view that combination therapy of CLR with

RIF might really be superior to other eradication protocols as suggested by the results of a retrospective clinical study in foals (Gigue`re et al., 2004). The absence of major drug interactions as shown in our recent pharmacokinetic study with tulathromycin and RIF should be confirmed before a combination treatment is launched in clinical practice (Venner et al., 2010).

87

Page 80: Antimicrobial  therapy in  horses:  a pharmacologist perspective

88

La cinquième édition (2013) du livre de référence en antibiothérapie vétérinaire avec

un chapitre chez le cheval